James Willard Hurst
YOU?
Author Swipe
View article: Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis Open
Results of our COM suggest that dapagliflozin can reduce clinical events and their associated costs over a 3-year period when compared with a scenario without dapagliflozin. Cost offsets increased with each year, indicating that US commerc…